<table>
<thead>
<tr>
<th>Title</th>
<th>Effects of calcium phosphate nanocrystals on osseointegration of titanium implant in irradiated bone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Li, JY; Pow, EHN; Zheng, LW; Ma, L; Kwong, DLW; Cheung, LK</td>
</tr>
<tr>
<td>Citation</td>
<td>BioMed Research International, 2015, v. 2015, article no. 783894</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2015</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/210677">http://hdl.handle.net/10722/210677</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Radiotherapymaycompromisetheintegrationofimplantandcauseimplantloss.Implantsurfacemodificationshavethepossibility
ofpromotingcellattachment,cellgrowth,andboneformationwhichultimatelyenhancetheosseointegrationprocess.Thepresent
study aimed to investigate the effects of calcium phosphate nanocrystals on implant osseointegration in irradiated bone. Sixteen
rabbits were randomly assigned into control and nano-CaP groups, receiving implants with dual acid-etched surface or dual acid-
etched surface discretely deposited of nanoscale calcium-phosphate crystals, respectively. The left leg of all the rabbits received
15 Gy radiation, followed by implants placement one week after. Four animals in each group were sacrificed after 4 and 12 weeks,
respectively. Implant stability quotient (ISQ), ratio of bone volumetototalvolume (BV/TV), bone growth rate, and bone-to-implant
contact (BIC) were evaluated. The nano-CaP group showed significantly higher ISQ (week 12, $P = 0.031$) and bone growth rate
(week 6, $P = 0.021$; week 9, $P = 0.001$) than that in control group. No significant differences in BV/TV and BIC were found
between two groups. Titanium implant surface modified with CaP nanocrystals provides a potential alternative to improve bone
healing around implant in irradiated bone.

1. Introduction

The success of implant osseointegration depends on the quality and quantity of the surrounding bone [1]. Radio-
therapy has been considered as one of the predominant factors causing implant loss [2, 3]. It alters the circulation
and metabolism of bone. Irradiation injures the small blood vessels leading to persistent hypoxia and reduces the quantity
and activity of osteoblasts [4]. A number of studies showed that the failure rate of implants placed in irradiated bone was
higher than those in nonirradiated bone [5–7]. This finding was confirmed in our previous study on a rabbit model [8].
The radiation at 15 Gy demonstrated a significantly adverse effect on implant stability and BV/TV.

Implant surface modifications may promote cell attachment, cell growth, and bone formation which ultimately
enhances the osseointegration process. The surface modification includes physical method, chemical method, or a
combination of both [9]. The CaP coated implant has demonstrated enhanced osteoconductive properties in normal bone
[10, 11]. However, to our best knowledge no studies have investigated the osseointegration of CaP coated implant in
irradiated bone.

The present study investigated the stability and osseointegration of CaP coated implant using our radiation compromised rabbit model [8].

2. Materials and Methods

2.1. Animal Care and Grouping. The animal experiment was approved by the Committee on the Use of Live Animals
Table I: Timetable of radiation, implant surgery, injection, and sacrifice on the rabbits in different groups.

<table>
<thead>
<tr>
<th>Rabbit no.</th>
<th>Radiation</th>
<th>Implant surgery and measure ISQ</th>
<th>Inject alizarin red</th>
<th>Inject calcin green</th>
<th>Inject oxytetracycline</th>
<th>Sacrifice, measure ISQ, and fixation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group</td>
<td>4</td>
<td>Week 1</td>
<td>Week 0</td>
<td>Week 1</td>
<td>Week 2</td>
<td>Week 3</td>
</tr>
<tr>
<td>Nano-CaP group</td>
<td>4</td>
<td>Week 0</td>
<td>Week 1</td>
<td>Week 2</td>
<td>Week 3</td>
<td>Week 4</td>
</tr>
<tr>
<td>Control group</td>
<td>4</td>
<td>Week 1</td>
<td>Week 0</td>
<td>Week 3</td>
<td>Week 6</td>
<td>Week 9</td>
</tr>
<tr>
<td>Nano-CaP group</td>
<td>4</td>
<td>Week 0</td>
<td>Week 1</td>
<td>Week 6</td>
<td>Week 9</td>
<td></td>
</tr>
</tbody>
</table>

for Teaching and Research, The University of Hong Kong. Sixteen adult, male New Zealand white rabbits (8-9 months old) were randomly assigned into control and nano-CaP groups, eight in each. Rabbits in control group received implants with dual acid-etched surface (Osseotite, Biomet 3i Implant Innovations Inc., Palm Beach Gardens, FL, USA), while rabbits in nano-CaP group received implants with dual acid-etched surface discretely deposited of nanoscale calcium-phosphate crystals (Nanotite, Biomet 3i Implant Innovations Inc., Palm Beach Gardens, FL, USA). The timeline of treatment was presented in Table 1.

2.2. Radiation. Radiation on rabbits was performed by radiotherapists in Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, using the protocol reported in our previous study [8]. The tibial and femoral metaphysis region of left hind leg was subjected to a single dose of 15 Gy irradiation, whereas the other parts of the animals were protected. Electron beams of 9 MeV from a Varian Clinac 2100CD were delivered with a 15 × 15 cm² applicator at a source to surface distance of 60 cm.

2.3. Implant Surgery. Implant surgery was performed one week after radiation. Under general anesthesia, parallel walled titanium implants with screw threads (3.25 mm × 8 mm) were placed in tibial and femoral metaphysis following the standardized protocol reported in our previous study [8]. Each animal received two implants on irradiated leg, one implant on tibia and one on femur. Totally 16 control implants and 16 nano-CaP implants were placed by the same surgeon. After surgery, appropriate antibiotics and analgesics were administered. Four rabbits in each group were sacrificed 4 weeks and 8 weeks after implant surgery, respectively. The implants together with 3–5 mm surrounding bone were harvested en bloc and fixed in 10% neutral formaldehyde. The timetable of radiation, implant surgery, fluorochrome labeling injection, and sacrifice is shown in Table 1.

2.4. Implant Stability Measurement. Resonance frequency analysis (RFA) device (Osstell; Integration Diagnostics, Savedalen, Sweden) was used to measure implant stability quotient (ISQ). Primary stability (ISQps) represented the ISQ value that was immediately measured after implant placement while secondary stability (ISQss) represented the ISQ value that was measured before sample retrieval.

2.5. Microcomputed Tomography (Micro-CT). After being fixed in the formaldehyde for 2 days, the samples were wrapped in Parafilm (SERVA Electrophoresis GmbH, Heidelberg, Germany) and subjected to micro-CT assessment (Skyscan-1076 X-ray microtomograph, Sky scans, Kontich, Belgium). The samples were scanned at energy of 101 kV and intensity of 96 mA with a resolution of 9 mm pixel using an aluminum filter (1 mm). A threshold was selected to differentiate the titanium implant, bone, and background using the protocol described in our previous study [8]. The bone surrounding the implant at a distance of 180 µm from the implant surface was analyzed, and the bone volume/total volume (BV/TV) was measured.

2.6. Fluorochrome Labeling. Three kinds of fluorochrome labeling, including alizarin red (25 mg/kg), calcin green (30 mg/kg), and oxytetracycline (50 mg/kg), were injected in chronological order (Table I). For the rabbits sacrificed at week 4, the fluorochrome labeling was injected at week 1, week 2, and week 3, respectively. For the rabbits sacrificed at week 12, the fluorochrome labeling was injected at week 3, week 6, and week 9, respectively. After sacrifice, samples were embedded with methyl methacrylate (MMA, Technovit 7500, Kulzer, Hamburg, Germany). The embedded sample was sawed along the long axis of implant into a section with 200–500 µm thick, which was then polished to about 100 µm. The prepared slides were examined under fluorescent microscopy (FluoView FV 1000; Olympus, Tokyo, Japan). The bone growth rate was calculated as the average distance between every two fluorochrome-labeled lines over the known time interval of two corresponding injections.

2.7. Histomorphometric Analysis. After fluorescent microscopy examination, the slides were stained with toluidine blue for 30 min. Histomorphometrical analysis was performed using a camera-equipped light microscope system (Eclipse LV100POL, Nikon, Japan) and a computerized image analyzer (NIS-Elements AR 3.00). Bone-to-implant contact (BIC) was calculated as the length of the bone in direct contact with the implant over the implant length.

2.8. Statistical Analysis. All measurements were conducted by one trained, blinded, and calibrated examiner (single measures intraclass correlation coefficient > 0.60). Repeated measures ANOVA (SPSS Inc., Chicago, IL, USA) were used.
Table 2: Values of implant primary stability (ISQps), secondary stability (ISQss), ratio of bone volume to total volume (BV/TV), and percentage of bone to implant contact (BIC).

<table>
<thead>
<tr>
<th>Group</th>
<th>ISQps</th>
<th>ISQss</th>
<th>BV/TV (%)</th>
<th>BIC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group (4 w)</td>
<td>65.25 ± 8.01</td>
<td>71.25 ± 4.98</td>
<td>55.57 ± 8.08</td>
<td>61.8 ± 8.1</td>
</tr>
<tr>
<td>Nano-CaP group (4 w)</td>
<td>63.75 ± 6.23</td>
<td>69.63 ± 5.15</td>
<td>53.31 ± 7.35</td>
<td>57.9 ± 8.8</td>
</tr>
<tr>
<td>Control group (12 w)</td>
<td>63.13 ± 5.54</td>
<td>74.25 ± 6.14</td>
<td>64.16 ± 8.20</td>
<td>64.3 ± 9.7</td>
</tr>
<tr>
<td>Nano-CaP group (12 w)</td>
<td>64.38 ± 7.37</td>
<td>78.25 ± 8.63</td>
<td>65.59 ± 8.54</td>
<td>70.2 ± 8.6</td>
</tr>
</tbody>
</table>

Figure 1: Micro-CT 3D images. (a) Control implant at week 4; (b) nano-CaP implant at week 4; (c) control implant at week 12; (d) nano-CaP implant at week 12. Green color represents implant surface and grey color represents bone.

3. Results

3.1. Clinical Assessment. All sixteen rabbits completed the experiment uneventfully. No postoperative complications were observed till sacrifice. The implants remained submerged and soft tissues were clinically healthy.

3.2. Implant Stability. No significant difference in primary stability (ISQps) was found among all groups at baseline (Table 2). The secondary stability (ISQss) was significantly higher than ISQps in all the groups (P < 0.001). Significant difference of the secondary ISQ (ISQss) between control and nano-CaP groups was not detected at week 4 (P = 0.602), but at week 12 (P = 0.031). When compared groups from the two time points, the nano-CaP implant groups showed that ISQss at week 12 was significantly higher than that at week 4 (P = 0.004).

3.3. Micro-CT. The representative images of micro-CT three-dimensional (3D) models of bone formation around implants are shown in Figure 1. The BV/TV at week 12 was significantly higher than that at week 4 in both groups (control: P = 0.042; nano-CaP: P = 0.005) (Table 2). No significant difference of BV/TV was found between control and nano-CaP groups at week 4 (P = 0.579) and week 12 (P = 0.724).

3.4. Fluorescence Observation. Fluorescence microscopy images are shown in Figure 2 and the measurements of bone growth rate are shown in Table 2. Comparing bone growth rates between different time points, the control groups showed that the growth rates at weeks 2 and 3 were marginally significantly higher than that at week 1 (P = 0.050), but no significant differences were found at later stages among weeks 3, 6, and 9 (P = 0.700). The nano-CaP groups showed a stable bone growth rate in the first 3 weeks (P = 0.742), but the growth rates at weeks 6 and 9 were significantly higher than the rate at week 3 (P = 0.022).

When compared the nano-CaP and control groups, no significant differences of bone growth rates were found in the first three weeks. At later stages, the bone growth rate of the nano-CaP group was significantly higher than that of control group at week 6 (P = 0.021) and week 9 (P = 0.001) (Table 3).

3.5. Histomorphological Analysis. Histological images showed that implants of control and nano-CaP groups were
well integrated with the surrounding bone. No inflammation was observed. The new bone was directly in contact with the implant surface (Figure 3). No change in BIC was found in the control group ($P = 0.158$), while there was a significant increase in BIC in the nano-CaP group from week 4 to week 12 ($P = 0.009$) (Table 2). No significant differences were found between control and nano-CaP groups at week 4 ($P = 0.390$) and at week 12 ($P = 0.184$) (Table 2).

4. Discussion

Rabbit has been used in many studies to investigate implant osseointegration in irradiated bone [7, 8, 12]. Our previous study using the same animal model demonstrated a dose-dependent effect of radiation on bone healing around dental implants [8]. The implant stability and bone volume was significantly compromised by a single dose of 15 Gy radiation [8].

Different surface modifications for titanium implants have been advocated to shorten the time of osseointegration [13, 14]. Calcium phosphate (CaP) is reported to promote cell attachment, proliferation, differentiation, and the production of extracellular matrix (ECM) in vitro [15, 16]. The favorable property of CaP coating might be due to the similarity of chemical composition between CaP coating and natural bone [17]. CaP coatings on titanium surface simulate the organic and inorganic components of natural bone tissue, which guides bone formation along the implant-bone interface [18]. CaP dissolved and delivered into the peri-implant region also raises the saturation level of body fluid and results in deposition of biological apatite on the surface of implants [19]. Nano-CaP implants, on the other hand, might have the potential of enhancing the “secondary” stability. This might be clinically useful not only for patients who had radiotherapy but also in other compromised bone conditions such as osteoporosis or inadequate bone height.

A number of studies have investigated discrete crystalline deposition (DCD) of calcium phosphate on implant surface; however, its effect on osseointegration was controversial. Most of the studies showed that nano-CaP coating of titanium surface could promote bone formation on implant surface, raise the torque required to remove implants, and increase BIC [20–23]. However, some studies found that the nano-CaP coating did not enhance early bone tissue integration in animal [24, 25] and clinical studies [26]. The discrepancy might be due to the different experimental model and time points for assessment. While most of the studies which assessed the osseointegration at or before week 4 did not find significant difference between nano-CaP group and control group, the long-term studies with the observation done after several months detected a difference. The present study showed no difference in secondary stability value at week 4, while the significantly higher ISQs value was detected in nano-CaP group at week 12. Our study also found that the
bone growth rate was significantly higher in nano-CaP group at week 6 and week 9. The identical results of increased ISQ and bone growth rate at the late stage of the present study suggested that nano-CaP surface modification may improve osseointegration in longer term rather than in early stage after implant placement. The present study did not find any differences in BIC and BV/TV between nano-CaP and control groups. This might be due to the limitation of sample size and observation time. A further study using a larger sample size with longer observation period is necessary.

5. Conclusions

Titanium implant surface modified with CaP nanocrystals may have potential to improve implant osseointegration in irradiation compromised bone. Further study with larger sample size and longer observation period is necessary.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors greatly acknowledge Biomet 3i Implant Innovations Incorporation for sponsoring the implants; the help of Dr. Dan LIU in implant surgery; technical assistance from the laboratory animal unit of the Faculty of Medicine, The University of Hong Kong; the Department of Clinical Oncology, Queen Mary Hospital; the micro-CT laboratory of the Department of Orthopaedics and Traumatology, The University of Hong Kong; the hard tissue laboratory of the Faculty of Dentistry, The University of Hong Kong.

References


